Epithalon Dosage: The Studied Numbers and Why They Are Uncertain
Epithalon, also spelled epitalon, is a four-amino-acid peptide, Ala-Glu-Asp-Gly, marketed as a longevity and telomere compound. People searching for a dose want a number, so here it is up front: the research used 5 to 10 mg per day in short courses. What that number does not come with is the thing that would make it trustworthy, a set of dose-ranging trials that tested different amounts and measured what happened. This guide gives the studied protocol and the practical math, then explains why the evidence behind it is thinner than the marketing suggests.
The dose used in the research
The recurring figure across the original epithalon work is 5 to 10 mg per day, given by injection as a short course. The typical course is 10 consecutive days, sometimes extended toward 20, and repeated cyclically rather than taken continuously. Community protocols for the synthetic peptide mirror that: 5 to 10 mg daily, subcutaneously, for 10 to 20 days, once or twice a year.
Treat those numbers as a convention copied from a small body of source studies, not as an optimized dose. No published trial has compared, say, 5 mg against 10 mg against 20 mg of the synthetic tetrapeptide and reported which one does more on a defined outcome. The dose is inherited, not derived.
Reconstitution and the practical math
Epithalon ships as a freeze-dried powder, commonly in 10 mg or 50 mg vials, and is reconstituted with bacteriostatic water. The arithmetic is straightforward once you fix the concentration:
- 50 mg vial + 5 mL water = 10 mg/mL. A 5 mg dose is 0.5 mL; a 10 mg dose is 1 mL.
- 10 mg vial + 2 mL water = 5 mg/mL. A 5 mg dose is 1 mL.
- On an insulin syringe marked in units, 1 mL is 100 units, so at 10 mg/mL a 5 mg dose is 50 units.
Add the water slowly down the side of the vial, let it dissolve without shaking, and refrigerate the reconstituted vial. The step-by-step is in how to reconstitute peptides, the numbers are in the peptide calculator, and shelf life is in storage.
Course length and cycling
The standard course is short. Ten days is the number that appears most often, with some protocols running to 20, and the course is repeated on a schedule such as twice a year. That cyclical pattern is how the original studies were designed; it is not a conclusion drawn from comparing continuous and intermittent dosing, because that comparison has not been published for epithalon in humans.
There is a mechanistic reason the exact schedule is hard to pin down. The tetrapeptide has a very short life in the bloodstream, on the order of minutes, and the proposed mechanism is not sustained receptor occupancy but a gene-regulatory effect, with the peptide reported to influence gene expression. If that is how it acts, then plasma half-life tells you little about how to space doses, which is precisely why a schedule copied from convention should not be mistaken for an optimized one.
Route: what was actually studied
The human work used injection, subcutaneous or intramuscular. Oral capsules and nasal sprays are sold, and they are more convenient, but there is no human pharmacokinetic data establishing how much of an oral or intranasal epithalon dose survives to reach the circulation. For a small peptide that is rapidly degraded, that is a real gap, not a technicality. If the point is to reproduce the studied protocol, the studied route is injection.
The epithalamin confusion that inflates the evidence
This is the single most important thing to understand before reading any epithalon claim. There are two different substances with similar names. Epithalamin is a polypeptide complex extracted from the pineal gland, a mixture. Epithalon, or epitalon, is one defined synthetic tetrapeptide, AEDG, designed as an analog of that extract.
The larger and more impressive human results, including the long-term follow-ups reporting effects on melatonin rhythm and on mortality in elderly cohorts, were done with epithalamin the extract. Those results are routinely presented on sales pages as if they belong to the synthetic tetrapeptide. They do not. When you strip the extract data back out, the human evidence base specific to the synthetic AEDG peptide is small and comes overwhelmingly from one research program.
The telomerase claim, at its source
The headline claim for epithalon is telomerase activation and telomere lengthening. It comes from Khavinson's laboratory in St Petersburg, which reported in 2003 that epithalon induced telomerase activity and elongated telomeres in cultured human somatic cells, and in a follow-up that treated fibroblasts divided past their normal Hayflick limit, completing more population doublings than controls.
Those are genuine published experiments. They are also in-vitro work from a single group, reported largely in Russian-language journals, and independent laboratories have not built a large replication record around the synthetic tetrapeptide. More to the point for anyone considering a dose: making cells in a dish express more telomerase is a molecular observation, not evidence that injecting the peptide extends human lifespan or healthspan. No clinical trial has shown that outcome for epithalon. The broader context is in peptides for longevity and peptides for anti-aging.
The melatonin and sleep angle
Because epithalon is derived from a pineal-gland analog, it is often tied to melatonin and sleep. The pineal connection is real in the sense that the parent extract, epithalamin, was reported to normalize the daily melatonin rhythm in older subjects. As with the longevity data, that finding sits with the extract, and its transfer to the synthetic peptide is an assumption rather than a demonstrated effect. If sleep is the actual goal, the compounds with more direct evidence are covered in peptides for sleep. The related synthetic pineal peptide is discussed in pinealon.
Safety, legality and supply
The short-course studies reported good tolerability, with no notable adverse effects at the 5 to 10 mg doses used. That is reassuring as far as it goes, but small short-term studies from one group are not a full safety profile, and there is essentially no long-term safety data for repeated epithalon use in humans.
Epithalon is not approved as a drug anywhere and is not on the FDA list of bulk drug substances eligible for pharmacy compounding. It is sold only as a research chemical, so it cannot lawfully be marketed for human use, and no regulator has checked the purity, sterility or labeling of any product on sale. See legal status of research peptides, FDA-approved peptides, and for technique how to inject peptides. The overview page is epitalon, and a head-to-head is in epithalon vs MOTS-c.
The bottom line
If you want the studied epithalon protocol, it is 5 to 10 mg per day by injection for a 10-day course, repeated cyclically. That is a real answer, and it is also a borrowed one, inherited from a small body of work rather than optimized in dose-ranging trials. The telomerase story that sells the peptide comes from cell experiments in a single laboratory, and the most impressive human numbers belong to a different substance, the pineal extract epithalamin, not to the synthetic tetrapeptide you would actually be injecting. Know the dose, and know exactly how much weight the evidence behind it can bear.
Frequently Asked Questions About Epithalon
The dose that appears in the original research is 5 to 10 mg per day given as a short course, most often 10 consecutive days, sometimes repeated once or twice a year. Community injection protocols usually copy those numbers, 5 to 10 mg daily subcutaneously for 10 to 20 days. It is worth being clear about what those figures are: they come from one research group’s protocols, not from dose-ranging trials that compared doses and measured outcomes, so there is no established optimal dose for the synthetic peptide.
Epithalon comes as a lyophilized powder, commonly in 10 mg or 50 mg vials, and is dissolved in bacteriostatic water. A 50 mg vial with 5 mL of bacteriostatic water gives 10 mg per mL, so 0.5 mL is a 5 mg dose and 1 mL is a 10 mg dose. A 10 mg vial with 2 mL gives 5 mg per mL, so 1 mL is a 5 mg dose. Add the water slowly against the vial wall, do not shake, and refrigerate after mixing. See our reconstitution guide and peptide calculator for the arithmetic.
The recurring pattern in the source research is a 10-day course, occasionally extended to 20 days, repeated on a cyclical basis such as twice a year rather than taken continuously. The rationale for cycling is not a validated pharmacokinetic one; it simply reflects how the original studies were run. Nobody has published a comparison of continuous versus cyclical epithalon in humans with a functional endpoint, so cycle length is a convention, not a finding.
The research used injection, subcutaneous or intramuscular, and that is the only route with any human data behind it. Oral and intranasal epithalon products are sold, but the tetrapeptide is small and rapidly broken down, and there is no human pharmacokinetic work showing what fraction of an oral or nasal dose reaches the bloodstream intact. If you are copying the studied protocol, the studied route is injection.
That claim traces almost entirely to one group. Khavinson’s laboratory in St Petersburg reported in 2003 that epithalon induced telomerase activity and telomere elongation in cultured human cells, and a follow-up reported treated fibroblasts dividing past their usual limit. Those are in-vitro findings from a single research program, published largely in Russian-language journals, and independent replication of the effect for the synthetic tetrapeptide has been limited. Telomere lengthening in a dish is also not the same as a longer or healthier life in a person, which no trial has shown for epithalon.
No, and the difference is where most of the overstated evidence comes from. Epithalamin is a polypeptide extract of the pineal gland. Epithalon, also spelled epitalon, is a single synthetic tetrapeptide, Ala-Glu-Asp-Gly or AEDG, developed as a defined analog of that extract. The larger human studies, including the long-term work often cited for reduced mortality in the elderly, used epithalamin the extract, not epithalon the synthetic peptide. Claims that transfer the extract’s results onto the tetrapeptide are conflating two different substances.
Epithalon is not an approved drug anywhere and is not on the FDA list of bulk substances eligible for pharmacy compounding. In the United States it is sold only as a research chemical, which means it may not lawfully be marketed for human consumption and no regulator has verified the purity, sterility or actual content of any vial. Reported tolerability in the small short-course studies was good, but that is not the same as an established safety profile.